Higher Serum PD‐L1 Level Predicts Increased Overall Survival With Lapatinib vs Trastuzumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Higher Serum PD‐L1 Level Predicts Increased Overall Survival With Lapatinib Versus Trastuzumab in the CCTG MA.31 Phase 3 Trial
Cancer 2020 Sep 10;[EPub Ahead of Print], P Moku, L Shepherd, SM Ali, K Leitzel, WR Parulekar, L Zhu, S Virk, D Nomikos, S Aparicio, K Gelmon, J Drabick, L Cream, ES Halstead, TM Umstead, D Mckeone, H Polimera, A Maddukuri, A Ali, V Nagabhairu, J Poulose, N Pancholy, H Spiegel, BE Chen, A LiptonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.